Author

W Rachel Duan

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5111016951

904 Additional Risankizumab Therapy Is Effective in Patients With Moderately to Severely Active Ulcerative Colitis Who Did Not Achieve Clinical Response to Initial 12-week Induction Therapy: an Analysis of Phase 3 Inspire and Command Studies

2024 · Remo Panaccione, Gil Melmed, et al. · Gastroenterology · 2

984 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 Command Study

2024 · Stefan Schreiber, Remo Panaccione, et al. · Gastroenterology · 2

Tu1730 LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 104-WEEK RESULTS FROM THE FORTIFY STUDY

2023 · Remo Panaccione, David T. Rubin, et al. · Gastroenterology · 2

P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results

2026 · Raja Atreya, Edouard Louis, et al. · E-Posters

Su1638 EFFICACY AND SAFETY UP TO 3 YEARS OF RISANKIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM PHASE 3 COMMAND OPEN-LABEL EXTENSION STUDY

2026 · Raja Atreya, Edouard Louis, et al. · Gastroenterology

Su1638 EFFICACY AND SAFETY UP TO 3 YEARS OF RISANKIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM PHASE 3 COMMAND OPEN-LABEL EXTENSION STUDY

2026 · Raja Atreya, Edouard Louis, et al. · Gastrointestinal Endoscopy

Su1761 EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION

2024 · Marc Ferrante, Remo Panaccione, et al. · Gastroenterology

117 - 52-weeks Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-weeks Iv Risankizumab Induction

2023 · Geert D’Haens, Remo Panaccione, et al. · Gastroenterología y Hepatología

Works count: 8

Citation count: 6

H-index: 2

I10-index: